Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

28.88USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$28.88
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
74,737
52-wk High
$35.48
52-wk Low
$21.27

Latest Key Developments (Source: Significant Developments)

Theravance Biopharma Says Renee Gala Resigns As CFO
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA SAYS ON OCT 3, RENEE D. GALA NOTIFIED CO OF HER RESIGNATION AS CHIEF FINANCIAL OFFICER EFFECTIVE ON JANUARY 2, 2019 - SEC FILING.  Full Article

Theravance Biopharma Reports Qtrly Loss Per Share $0.76
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA, INC. REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.THERAVANCE BIOPHARMA INC - QTRLY LOSS PER SHARE $0.76.THERAVANCE BIOPHARMA INC - QTRLY TOTAL REVENUE $23.5 MILLION VERSUS $3.5 MILLION.THERAVANCE BIOPHARMA - GUIDANCE ON OPERATING LOSS EXCLUDING NON-CASH SHARE-BASED COMPENSATION FOR FY REMAINS UNCHANGED.  Full Article

Theravance Biopharma Reports Positive Top-Line Four-Week Data From Phase 2 Trial Of Td-9855
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA REPORTS POSITIVE TOP-LINE FOUR-WEEK DATA FROM PHASE 2 TRIAL OF TD-9855 FOR THE TREATMENT OF SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION.THERAVANCE BIOPHARMA INC - THERE WERE NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED, AND TD-9855 WAS GENERALLY WELL TOLERATED IN STUDY.THERAVANCE - CONCLUDED DISCUSSIONS WITH FDA ON DESIGN OF PIVOTAL PHASE 3 REGISTRATIONAL PROGRAM, TO INITIATE PROGRAM IN LATE 2018 OR EARLY 2019.  Full Article

Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA.THERAVANCE BIOPHARMA INC - ‍FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH U.S. FDA FOR USE OF TRELEGY ELLIPTA​.  Full Article

Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Theravance Biopharma Inc -:Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease.Theravance Biopharma Inc - ‍NDA is supported by companies' Phase 3 program for revefenacin​.  Full Article

Theravance Biopharma posts Q3 loss of $1.27 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Theravance Biopharma Inc :Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update.Q3 revenue $4.3 million versus i/b/e/s view $4.6 million.Cash, cash equivalents and marketable securities, excluding restricted cash, totaled $434.4 million as of september 30, 2017​.Qtrly basic and diluted net loss per share $1.27‍​.  Full Article

Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Mylan Nv :Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting.Theravance Biopharma Inc - ‍remain on track to submit an NDA for Revefenacin Q4 of 2017​.Theravance Biopharma Inc - ‍results demonstrated statistically significant and clinically meaningful improvements for revefenacin over placebo ​.Theravance Biopharma Inc - ‍both doses of revefenacin had comparable rates of adverse events to placebo​.  Full Article

BRIEF-Theravance Biopharma Reports Qtrly Loss Per Share $1.22

* THERAVANCE BIOPHARMA, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE